BNET Industries
Chiron Corp. is in the Pharma Industry
Latest News and Analysis
Swivelhead spindle VMC designed fop single setups—Chiron America
With seven CNC-controlled axes, Chiron's FZ 12K S with swivelhead offers various machining options in one setup, from the bar. Capable of high-precision, automated, six-side machining, the VMC is suited for machining watch casings, medical parts or hydraulic components. Medical applications for this machine include orthopedic devices, such as larger...
Novartis Delivers Dynamic Sales and Earnings Growth in the First Nine Months of 2006, Reaffirms Outlook for Record Full-Year Results
-- Group continues double-digit expansion -- Nine-month net sales up 14% (+15% lc) to USD 27.0 billion on strong underlying growth and acquisition-related contributions -- Operating income rises 17%, supported by all divisions...
Former Chiron Exec Joins APT Pharmaceuticals as CEO
FOSTER CITY, Calif. -- APT Pharmaceuticals Inc. (http://www.aptbio.com) has named the former chief medical officer of Chiron BioPharmaceuticals, Stephen G. Dilly, M.B.B.S., Ph.D., as chief executive officer.
Research and Markets: A Fourth Division for Novartis under the Title Vaccines & Diagnostics, Will Be Created After the Acquisition of Chiron Corporation
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41412) has announced the addition of Espicom Business Intelligence's Novartis Prospects to 2010 to their offering.
Application: Fast, accurate 5-axis machining.
Staff From the start, in 1985, the need for five-axis machining was apparent, says Rob Bujeaud, vice-president of manufacturing for Turbocam and its recently created high-production division, TAPS Turbocam Automated Production Systems. Staff...
Chiron Shareholders Approve Novartis Acquisition
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ:CHIR) today announced that Chiron shareholders have approved the amended merger agreement under which Novartis AG (NYSE:NVS) will acquire all Chiron shares it doesn't already own for $48.00 per share in cash. At a special meeting of Chiron shareholders held today, the merger was approved...
Chiron Announces Initiation of Phase 1 Trial for CHIR-265 In Melanoma; Clinical Testing of Novel Oncology Compound Begins in Patients with Skin Cancer
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ:CHIR) today announced the initiation of a Phase 1 clinical trial of CHIR-265, a selective Raf kinase inhibitor, in patients with melanoma.
Proxy Advisory Services Recommend Shareholders Vote in Favor of Chiron's Amended Merger Agreement with Novartis
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ:CHIR) today announced that three independent proxy advisory firms, Institutional Shareholder Services, Proxy Governance, and Glass Lewis & Co., have recommended that Chiron shareholders vote in favor of the company's amended merger agreement with Novartis AG (NYSE:NVS). As announced on April 3, Novartis has increased...
ValueAct Capital to Vote Its Chiron Shares in Favor of Revised Novartis Merger Agreement
SAN FRANCISCO and BOSTON -- ValueAct Capital today announced its intention to vote for the amended merger agreement under which Novartis AG would acquire, for $48.00 per share, the 56 percent of Chiron Corporation it does not already own.
Schaeffer's S&P 500 Index Hot Stocks Features Archer-Daniels-Midland, Chiron, Phelps Dodge, RadioShack, and Bausch & Lomb
CINCINNATI -- Among the stocks featured in the April 3 edition of Schaeffer's S&P 500 Index Hot Stocks are Archer-Daniels-Midland (NYSE:ADM), Chiron (NASDAQ:CHIR), Phelps Dodge (NYSE:PD), RadioShack (NYSE:RSH), and Bausch & Lomb (NYSE:BOL). Schaeffer's S&P 500 Index Hot Stocks is just one of the many free market commentaries written everyday...
Chiron Statement on Recommendations by Proxy Advisory Services
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ: CHIR) today noted that two proxy advisory services have reached opposite conclusions regarding their voting recommendations to Chiron shareholders in connection with the proposed acquisition of Chiron by Novartis AG (NYSE: NVS). A special meeting of Chiron shareholders will be held on April 12,...
ValueAct Capital Again Refuses to Meet with Chiron, Condemns Its Use of Scare Tactics to Win Support for Novartis Offer
SAN FRANCISCO & BOSTON -- ValueAct Capital today announced that it has declined a second request by Chiron Corporation (Nasdaq: CHIR) to accept a meeting as part of the company's roadshow aimed at convincing Chiron shareholders to support Novartis AG's $45 per share offer for the 56 percent of Chiron...
Chiron Recalls and Withdraws MORUPAR® MMR Vaccine from Italian and Developing World Markets — Chiron Also Revises 2005 Adjusted EPS From $1.34 to $1.31 Per Share and GAAP EPS From $0.97 to $0.94 Per Share
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ: CHIR) today announced that it is recalling and withdrawing its measles, mumps and rubella MMR vaccine, MORUPARR. Chiron supplied approximately 5 million doses of MORUPAR vaccine in 2005, providing most of its production to a limited number of developing countries, largely via the United...
ValueAct Capital Refuses to Meet with Chiron Directors Except to Discuss Ways to Increase Shareholder Value beyond $45
SAN FRANCISCO & BOSTON -- ValueAct Capital today reiterated its strong opposition to the proposed acquisition by Novartis AG, for $45 per share, of the 56 percent of Chiron Corporation (Nasdaq: CHIR) that Novartis does not already own, and said it would not meet with Chiron directors except to discuss...
Chiron Response to ValueAct Letter
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ:CHIR) today issued the following statement in response to a letter received today from ValueAct Capital:
Chiron Schedules Special Meeting of Stockholders to Approve Merger With Novartis
EMERYVILLE, Calif. -- First graph, first sentence of release should read: Chiron Corporation (NASDAQ:CHIR) today announced that it will convene a special meeting of stockholders on Wednesday, April 12, 2006, to vote to approve its proposed merger with Novartis AG (sted Tuesday, April 18, 2006).
Bacteria invade UK medicine plant!(Chiron)(Brief article)
THE BIOTECH INDUSTRY TOOK A QUALITY knockdown punch in late 2004 when Chiron, the nation's biggest manufacturer of flu vaccine, had its Liverpool, England plant shut down by the chief UK regulatory body, the Medicines and Healthcare Products Regula THE BIOTECH INDUSTRY TOOK A...
Chiron Announces Pandemic Influenza Vaccine Contract with the UK Government; Chiron Submits Pandemic Influenza Vaccine ``Mock-Up'' File to European Regulators
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ:CHIR) today announced that it has entered into a supply contract with the UK government for pre-pandemic influenza vaccine(1) for a stockpile based on the H5N1 avian influenza virus strain. Health authorities have identified H5N1 avian influenza as a strain with pandemic potential.
Chiron Updates Delivery Expectations for U.S. Government H5N1 Vaccine Stockpile Contract
EMERYVILLE, Calif. -- Chiron Corporation (NASDAQ:CHIR) today announced that the U.S. Department of Health and Human Services HHS agreed to extend delivery terms for a stockpile of H5N1 bulk influenza vaccine(1) for the U.S. government. In October 2005, Chiron announced that it had entered into a contract with the U.S....
Chiron Confirms Proposed Purchase of BETASERON Assets by Schering AG Under Change-in-Control Option
EMERYVILLE, Calif. -- Chiron Corporation (Nasdaq:CHIR) today announced that Schering AG has provided formal notice to Chiron of its intention to exercise its option under its collaboration agreement with Chiron to purchase or lease all assets used by Chiron in the manufacture for Schering of BETASERONR interferon beta-1b products and...
- Next »
- page 1 of 19
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- vaccine (32 results)
- Novartis AG (19 results)
- FDA (18 results)
- agreement (13 results)
- Biotechnology (12 results)
- virus (10 results)
- collaboration (10 results)
- health care (9 results)
- job (7 results)
- Webcast (7 results)
- GAAP (7 results)
- stock (7 results)
- S&P 500 (6 results)
- Genentech Inc. (6 results)
- Roche Holding AG (6 results)
- analysis (5 results)
- vision (5 results)
- clinical trial (5 results)
- board (4 results)
- Cell (4 results)
- merger (4 results)
- partnership (4 results)
- earnings (4 results)
- acquisition (4 results)
- Company (4 results)
- shareholder (4 results)
- finance (4 results)
- class action (3 results)
- compliance (3 results)
- patient (3 results)
- therapy (3 results)
- Call Transcript (3 results)
- influenza (3 results)
- Seeking Alpha (3 results)
- pharmaceutical company (3 results)
- Financial Accounting (3 results)
- net income (3 results)
- revenue (3 results)
- MedImmune Inc. (3 results)
Chiron Corp. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
